What question did this study set out to answer?

This research aims to compare the efficacy and tolerability of afatinib 30 mg versus 40 mg in patients with uncommon EGFR mutations in lung cancer.

February 2, 2026

View Full Paper

First-Line Afatinib 30 mg Versus 40 mg in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutations: Real-world Efficacy and Tolerability in Taiwan.

HHHui-Yang HungKaohsiung Medical University TLTai-Huang LeeKaohsiung Medical University CCCheng-Hao ChuangTamkang University

Key Points

This research aims to compare the efficacy and tolerability of afatinib 30 mg versus 40 mg in patients with uncommon EGFR mutations in lung cancer.
Comparative analysis of afatinib doses (30 mg vs 40 mg)
Evaluation of progression-free survival (PFS) and overall survival (OS)
Assessment of tolerability and safety profiles
Afatinib 30 mg demonstrated comparable efficacy to 40 mg
30 mg showed significantly longer PFS and OS
Lower-dose afatinib exhibited better tolerability among patients

Abstract

Afatinib 30 mg daily achieved comparable efficacy and better tolerability than 40 mg, with significantly longer PFS and OS in patients harboring compound or double-rare EGFR mutations. These findings suggest that lower-dose afatinib may optimize efficacy and safety in patients with uncommon EGFR-mutant NSCLC.

AIに質問

Bookmark

View Full Paper

Cite This Study

Hung et al. (Sun,) studied this question.

synapsesocial.com/papers/6980fe9bc1c9540dea810c29 https://doi.org/https://doi.org/10.21873/anticanres.17999

AIに質問

Bookmark

View Full Paper